Hair has become an important matrix for drug analysis, complementary to blood and urine as a matrix. A prolonged detection window makes hair analysis suitable for lhe detection of exposure to illegal and medicinal drugs for periods up to 12 months. In the present study, a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for drug screening in hair was developed and validated. To 20 mg of hair, 0.45 mL of acetonitrile/25 mM formic acid (5:95 v/v) and 50 pl. of deuterated internal standards were added, and the sample was incubated in a water bath at 37~ for 18 h. LC separation was achieved with a Zorbax SB-Phenyl column (2.1 x 100 ram, 3.5-pm particle). Mass detection was performed by positive ion mode electrospray LC-MS-MS and included the following drugs/metabolites: nicotine, cotinine, morphine, 6-monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, and methadone. Within-and between-assay relative standard deviations varied from 2.0% to 12% and 2.7% to 15%, respectively. The accuracies were in the range of-24% to 16%, and recoveries ranged from 25% to 100%. The LC-MS-MS method proved to be simple and robust for the determination of drugs in hair. It has been used for authentic samples in our laboratory in the past year.
Introduction
Blood and urine have traditionally been used as biological fluid for drug testing in most clinical and forensic toxicological situations. During the past two decades, there has been a considerable increase of analytical methods for determination of drug in other biological media such as oral fluid and hair. Hair has a longer surveillance window (months) compared to blood (hours to days) and urine (days to weeks), and can therefore be used as a complementary matrix. Provided affinity to con-* Author to whom correspondence should be addressed. E-mail: solfrid.hegstad@fhi.no. stituents such as melanin and keratin in hair, several drugs in blood are trapped in the growing hair during its formation. Drugs are also incorporated from sweat, sebum, and the external environment (1--4) . Subsequently, hair analysis has proved to be a useful and valuable indicator of medium/longterm exposure to illegal and medicinal drugs (2, (5) (6) (7) (8) . Hair analysis has been applied in the verification of drug-facilitated crimes (9) (10) (11) (12) , therapeutic monitoring (13) , forensic autopsies (6, 14) , driving license regranting (15) , and workplace drug testing (16, 17) . In addition, hair analysis can distinguish between chronic use and short-term exposure. The average hair growth of humans is approximately 1 cm per month. Segmental analysis (1-2 cm sections) may give a relatively certain statement about the time of drug intake.
In the treatment of opioid addiction, testing for drug use is important when assessing effectiveness (e.g., in controlled clinical trials). Traditionally, urine has been used to control side-drug use, resulting in patients submitting samples at relatively frequent, and often known, time intervals. This sampiing regime is rigid, "offensive", and makes manipulation possible. Hair samples can be taken at much longer time intervals and manipulation is much less likely. Hair can be substituted for urine samples, provided suitable analytical methods are used for the determination of relevant drugs.
Immunoassay, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-tandem mass spectrometry (LC-MS-MS) have previously been reported as screening methods in hair analysis (12, (18) (19) (20) (21) (22) (23) . Immunoassay techniques are less specific than chromatographic analysis, and a relatively limited range of immunoassay reagents are commercially available for the determination of forensically relevant compounds. GC-MS is a specific technique that requires derivatization and tedious sample extraction prior to analysis. LC-MS-MS is increasingly being used in forensic toxicology for the screening and quantification of a wide range of compounds in biological samples (24) . In 2004, Kronstrand et al. (22) established an LC-MS-MS screening method for the determination of 12 overdose-related drugs of abuse in human hair. Nicotine and cotinine were also included in the method. Two screening methods for the determination of benzodiazepines and benzodiazepine-like hypnotics by LC-MS-MS have recently been published (12, 23) .
In this paper, we present a simple, robust, and specific LC-MS-MS screening method for the simultaneous determination of 22 psychoactive medicinal drugs, illegal drugs, and their metabolites in human hair. The compounds included were nicotine, cotinine, morphine, 6-monoacetylmorphine (6-MAM), codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, and methadone. The LC-MS-MS method presented by Kronstrand et al. (22) in 2004 was used as a starting point for this method development. The method was used for drug monitoring of opioid-addicted patients where one group was treated with a naltrexone implant and the other group did not receive an implant. Patients in this study were using the GoMedical implant, previously shown to have a duration of up to six months with double implants and acceptable levels of side effects (25) (26) (27) . Hair analysis was used to monitor the enrolled patients for both chronic use or short-term exposure to illegal and medicinal drugs.
Material and Methods

Chemicals and reagents
Reference compounds were obtained from multiple pharmaceutical companies: cotinine, methamphetamine, MDMA, benzoylecgonine, zopiclone, and buprenorphine from Cerilliant Corp. (Austin, TX); methamphetamine, 7-aminonitrazepam, 6-MAM, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, buprenorphine, and alprazolam from Lipomed (Arlesheim, Switzerland); morphine, amphetamine, codeine, cocaine, meprobamate, benzoylecgonine, zolpidem, oxazepam, carisoprodol, and diazepam from Sigma-Aldrich (St. Louis, MO); morphine, amphetamine, codeine, cocaine, meprobamate, and methadone from NMD (Oslo, Norway); MDMA, 6-MAM, 7-aminonitazepam, 7-aminoclonazepam, and 7-aminoflunitrazepam from Alltech (State College, PA); nicotine and methadone from RBI (Natick, MA); zolpidem and alprazolam from Council of Europe (Strasbourg, France). The internal standards morphine-d3, amphetamine-du, 7-aminoflunitrazepam-dT, and diazepam-ds were purchased from Cerilliant. Standard compounds were stored according to supplier recommendations (solid substances mainly at room temperature, ampoules at 4~ All other solvents and inorganic chemicals were of HPLC or analytical grade from various commercial sources.
Standard solutions
For each compound, two separate stock solutions were prepared. With the exception of zopiclone and zolpidem, which were dissolved in acetonitrile, all the other compounds were dissolved in methanol. Calibrators and quality control (QC) sample solutions were prepared by appropriate dilutions of stock solutions with water. The stock and aqueous solutions were stored at -20~ and 4~ respectively. Spiked calibrator and QC samples were prepared by adding 50 ~L of aqueous calibrator or control solutions to 20 mg drug-free hair prior to incubation. The concentration ranges for the calibrator samples were 0.25, 0.5, 1.25, and 2.5 ng/mg (nicotine, cotinine, morphine, amphetamine, methamphetamine, codeine, MDMA, 6-MAM, cocaine, meprobamate, carisoprodol, and methadone) or 0.05, 0.125, 0.5, and 2.5 ng/mg (7-aminonitrazepam, benzoylecgonine, zopiclone, 7-aminoclonazepam, zolpidem, 7-aminoflunitrazepam, buprenorphine, oxazepam, diazepam, and alprazolam). QC samples were prepared in blank hair at low (0.08-0.38 ng/mg) and high (1.88 ng/mg) concentration levels.
Specimens
Spiked specimens were blank hair samples (blond-brown) obtained from laboratory personnel and family, after verbal consent. Drug-positive hair samples (n = 4) from autopsy cases at the Institute of Forensic Medicine (University of Oslo, Rikshospitalet, Oslo, Norway) were used for the within-assay precision study. The hair was cut into small pieces, and 20 mg hair was put into a 10-mL screw-capped glass tube.
Authentic specimens (n = 12) included in the study came from patients enrolled in an ongoing case-control study on naltrexone implants. One patient group was given double im- Figure 1 . Ion chromatograms from the lowest concentration calibrator.
plants from GoMedical Industries (Australia), while the other group did not receive implants. Interview data were scheduled to take place at baseline and after 6 months (28).
Hair samples were taken before inclusion in the naltrexone study and at follow-up after approximately 6 months. The samples were collected by cutting the hair from the back of the head, the vertex posterior. The hair samples were cut into 1 cm segments (7-25 mg per segment), and transferred into a 10-mL screw-capped glass tube.
Sample preparation
Washing procedure of authentic specimens: The hair segments were washed for 15 min with 2 mL 2-propanol, 3 x 15 min with 2 mL 0.01 M phosphate buffer (pH 6), and i x 15 min with 2 mL 2-propanol. The washing procedure was performed in a water bath at 37~ The hair samples were dried at room temperature. Hair samples (authentic, calibrators, and QC) were mixed with 0.45 mL of acetonitrile125 mM formic acid (5:95, v/v), and 50 pL of internal standard (500 ng/mL of morphine-d3, amphetamine-du, 7-aminoflunitrazepam-d7, and diazepam-d5) in 10-mL tubes with screw-caps (Schott, Mainz, Germany). After centrifugation (Labofuge 400R, Heraeus instruments, Osterode, Germany) at 2600 x g in I min, the samples were incubated in a water bath (GLS400, Grant, Cambridgeshire, England) at 37~ for 18 h. Finally, the samples were centrifuged at 2600 x g for I min, 200 pL of the supernatants was transferred to autosampler vials, and 10 IJL was injected into the LC-MS-MS system.
tC conditions
LC was performed using a Surveyor LC pump equipped with a Surveyor autosampler (Thermo Electron, Waltham, MA). Separation was performed on a Zorbax SB-Phenyl (2.1 x 100 ram, 3.5 pro) column (Agilent Technologies, Santa Clara, CA), using gradient elution at a flow rate of 0.25 mL/min with the solvents 25 mM formic acid (A) and 100% acetonitrile (B). The system was run in a linear gradient from 2% B to 20% B for 3 rain and increased to 90% B in 4 min, which was held for 2 rain. Re-equilibration of the HPLC column was achieved as 
MS-MS
A TSQ Quantum Discovery MAX triple-stage quadrupole MS (Thermo Electron) equipped with electrospray interface was used. Positive ionization was performed in the multiple reaction monitoring (MRM) mode. The spray voltage was 5.0 kV, the capillary temperature was 350~ the sheath gas was 40 psi, and auxiliary gas (nitrogen) pressure was 10 au (arbitrary units). Argon was used as the collision gas (20 psi). The appropriate MRM transitions, tube lens values and collisions energies for the individual analytes were determined by direct infusion into the mass spectrometer. The MRM transitions, the tube lens values, and collision energy for the measurement of the analytes and the internal standards are shown in Table I . System operation, data acquisition, and data processing were controlled using Xcalibur 1.4 (Thermo Electron). Analytes were identified by comparing the retention times of the respective MRM transitions with the retention times of the corresponding calibrators and QC samples.
Method validation
The four-point calibration curves were based on peak-height ratios of analytes and internal standard versus the calibrator standard's concentrations using a weighted (equal) 2rid-order regression line, which included the origin. Within-assay precision was estimated by analysis of 10 separate replicates of the lowest QC concentration level in a single assay. Between-assay precision and accuracy were determined by analysis of aliquots of each QC concentration at 10 different days over a 2-month period, one replicate in each assay. In addition, real samples with 6 replicates were used for the determination of withinassay precision. Limits of quantification (LOQ) were determined by analyzing 5 different drug negative hair specimens on 10 successive days, one replicate on each day. LOQ was defined as the analyte concentration giving a MRM transition signal height equal to that of the mean of the signal of the negative samples plus 10 standard deviations of these samples. In addition, drug-free hair samples supplemented with various concentrations of analytes (0.0025-0.05 ng/mg) were incubated and analyzed in 10 replicates to confirm that the S/N at the determined LOQ values were greater than 10:1. The recovery was determined with six replicates at the lowest QC concentration level. Recoveries were estimated by measuring peak heights obtained when the analytes were added before sample preparation with those obtained when the analytes were added after the incubation step. In both cases, the internal standard was added after incubation.
Specificity
To investigate the specificity of the method, high concentrations (I-30 IJglmL) of selected prescription drugs and illegal drugs were incubated in drug-free hair. The drugs tested (n = 72) were antidepressants, analgesics, antipsychotics, amphetamine, and opiate-related compounds.
Matrix effects
Matrix effects (ME) were evaluated by the method proposed by Matuszewski et al. (29) . The analyte signal in the spiked mobile phase was compared with the analyte signal in the matrix fortified after incubation, and the ME was defined as ME% = (extracted matrix height/mobile phase height) x 100. Five replicates of mobile phase and 5 replicates of hair (from 5 different individuals) extracts were analyzed. The concentrations corresponded to calibrator sample 3. w Matrix effect expressed as the ratio of the mean peak height of a compound spiked after incubation (set 2) to the mean peak height of the same compound standards (set I) multiplied by 100. A value of > 100% indicates ionization enhancement, and a value of < 100% indicates ionization suppression.
Results and Discussion
Method validation
Calibration curves were made for each compound for the concentration range listed in Table [ [. The ion chromatograms of blank hair spiked with analytes and internal standards at the level of the lowest calibrator are shown in Figure 1 . The withinassay precisions, between-assay precisions, accuracies, recoveries, and LOQs for the analytes are presented in Table II . The between-assay RSDs were 2.7%-15%, and the within-assay RSDs were 2.0%-12%. The accuracies were in the range
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-24% to 16% and recoveries ranged from 25% to 100%. The compounds with recoveries (< 50%) showed acceptable accuracy and precision. The recoveries were therefore considered sufficient for screening purposes. ficult to obtain blank hair without any trace of nicotine. Even though the signal of the lowest calibrator standard was higher than in the blank sample, the LOQ for nicotine was set three times higher than the lowest calibrator (Table II) . In cases where the exact concentration of nicotine may be critical, the lowest calibrator standard should be increased to 0.75 ng/mg.
Matrix effects
The matrix effects (ME %) ranged from 79% to 123% (Table   IV) , and RSDs for the peak heights of drugs were 1.7-4.6% and 2-25.4% in sets 1 and 2, respectively. The higher variability in set 2 than in set I indicated a matrix effect. The RSDs for set 2 using the peak height ratio of drug and internal standard showed improved RSDs for some of the drugs when compared to no correction with internal standard. The results indicate that the internal standard had a compensatory effect both on the precision and reliability of the quantification of these drugs. However the correction with internal standard had an opposite effect on the RSDs for 7-aminonitrazepam, zopiclone, methadone, oxazepam, carisoprodol, and alprazolam, which resulted in increased RSDs. The use of deuterated internal standard can partly overcome the problem of matrix effects. However, both the availability and the high costs of deuterated compounds limit their use. Hence, four deuterated internal standards were evaluated as be sufficient for this screening method. The observed matrix effects (i.e., approximately • 20% ion enhancement/ion suppression) were considered to be acceptable.
Application
To demonstrate the applicability of this method, hair samples were taken before and during a drug treatment program with a naltrexone implant. As an example, two participants were chosen to demonstrate the feasibility of the method, one with a naltrexone implant (Participant 1), and one without (Participant 2). After six months, another hair sample was taken and four segments of 1 cm each were obtained. All segments were positive for amphetamine (4.2, 2.7, 2.4, 1.8 ng/mg), methamphetamine (15.6, 9.2, 8.1, 6.0 ng/mg), and meprobamate (1.0, 0.7, 0.7, 0.5 ng/mg). The chromatograms in Figure 2A and 2B represent the analysis of the root segment (0-1 cm) before and after the implantation period. The patient did not report any use of amphetamine, methamphetamine, or meprobamate during this period.
Participant2. Before project inclusion, six segments of 1 cm length starting from the root were analyzed. According to the interview data, the patient used heroin regularly in the time before hair sampling. Small amounts of 6-MAM and morphine were detected in each segment; the calculated concentrations were above the LOQ at 0.0125 and 0.005 ng/mg, respectively, but below the lowest calibration standards at 0.25 ng/mg. The identities of the compounds are reliable but the results are not quantifiable.
The hair sample taken after six months was cut into six segments. All segments contained nicotine, cotinine, morphine (2.8, 2.6, 2.0, 1.2, 0.3, 0.2 ng/mg), and 6-MAM (1.2, 1.3, 1.5, 1.9 , 2.1, 3.1 ng/mg), respectively. Segments 1--4 contained codeine (0.5, 0.6, 0.4, 0.3 ng/mg). In segments 5 and 6 there were only low concentrations (> LOQ) of codeine. Most of the segments contained alprazolam and diazepam. The concentration was under our lowest calibration standard at 0.05 ng/mg. Cocaine and benzoylecgonine were also detected (> LOQ) in some of the segments. These findings corresponded to the patient's information from the interview data with the exception of MDMA, where some use of the compound was reported. There was no trace of this compound in the hair segments.
Conclusions
The LC-MS-MS screening method used in this study covers the simultaneous determination of 22 different compounds in hair samples. The method was proven to be simple, robust and has been already established for the analysis of authentic samples in our laboratory. Our experience with the method is good and it holds promise for clinical applications (i.e., long-term post-intake monitoring in research or in restrictive rehabilitation programs, and possible substitution for urine analysis).
